US to send experimental Ebola vaccine and drug to Uganda

News » Health

 US to send experimental Ebola vaccine and drug to Uganda

Last week, the United States sent a new generation of antiviral drug Remdesivir to Uganda. Gilead Sciences(GILD.O) and Mapp Biopharmaceutical Inc., an experimental Ebola antibody vaccine. 44, Reuters reported, citing US government sources.

There are currently no proven vaccines or treatments for Sudanese Ebola, one of four known Ebola viruses that cause hemorrhagic fever in humans. confirmed by the Ministry of Health of Uganda on September 20, is the largest of the Sudanese species since 2000.

Ugandan Health Minister Jane Root Aseng announced the US shipments at a meeting of African health officials last week in Kampala and said Remdesivir, which is widely used to treat COVID-19, and experimental monoclonal antibodies have been administered to healthcare workers.< br />
Providing treatments that protect the lives of healthcare workers can be critical to containing an outbreak, said Joel Montgomery, director of the U.S. Centers for Disease Control and Prevention's Division of Viral Special Pathogens and outbreak response manager.

“If health care workers will start to get sick and die, this will negatively affect the response”, — said Montgomery, who had just returned from a trip to Uganda.

For example, medical professionals may not be willing to help respond, he said in a telephone interview.

The World Health Organization said in a statement that the agency is working with partners in Uganda to build infrastructure for clinical trials, support the use of untested antiviral drugs and monoclonal antibodies, and will collect data on their effectiveness.

Major Zairean Ebola outbreak species in West Africa in 2014-2016 resulted in effective vaccines and treatments, but there are no proven treatments or vaccines for the Sudanese species.

On October 4, San Diego-based Mapp Biopharmaceutical received a $110 million contract from the US government's Biomedical Advanced Research and Development Administration (BARDA) for the advanced development and potential procurement of MBP134, a combination of monoclonal antibodies.

"Remdesivir" in monkeys showed that each of the drugs, given alone, saved 20% of animals infected with Sudanese Ebola species, but when used together, 80% of infected animals survived.

MBP134 is currently undergoing early trials safety in healthy human volunteers, said Mapp President Larry Zeitlin in an email. upon request, the company does provide its drug free of charge for humanitarian use, pending regulatory approval. He declined to say how many doses the company provided.

Follow us on Telegram

Add a Comment

Your email address will not be published. Required fields are marked *